Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Stroke -- Ignore unavailable to you. Want to Upgrade?

To: russet who wrote (30)	1/19/2004 7:41:07 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 70

re. Toronto Western Hospital and the University of Toronto, work with TRPM7...... >> comments? << Looks very interesting. The news didn't seem to be widely commented on? Or is that my imagination? I did an Edgar search and came up empty (investment-wise).

To: russet who wrote (30)	1/19/2004 11:22:02 PM
From: John McCarthy	Read Replies (1) \| Respond to of 70

russett - terrific article - thanks for posting .... did a google search to try and find out what (if any) companies were using this ..... - could not find any trials .... - found universities/research ranging from Urvine CA Howard Huges Medical hhmi.org Homburg, Germany jbc.org - found 1 private company whose link is below ... i.e. at least they know how to spell it .... syntapharma.com - the following is way off but you never know .... there is a disease called (never heard of) HYPOCALCEMIA: DIAGNOSIS AND TREATMENT Chapter 7 - Lorraine A. Fitzpatrick, M.D. endotext.org now my point is - perhaps a company researching the disease might have some knowledge of TRPM7 but then again - maybe not .... <<<<<<<<<<< A rare finding is primary familial hypomagnesemia, which usually is diagnosed at a very young age. Hypomagnesemia with secondary hypocalcemia due to a mutation in TRPM6 was described simultaneously by 2 research groups 13,14. TRPM6 is a protein of the long transient receptor potential channel (TRPM) family and highly similar to TRPM7. TRPM7 is a bifunctional protein combining calcium- and magnesium-permeable cation channel activities with protein kinase activity. TRPM6 is present in both kidney tubules and intestinal epithelia and maps to chromosome 9q. This autosomal recessive disorder is treatable with life-long magnesium supplementation. Recognition and treatment can prevent long-term neurological defects. Patients can sometimes present in a triad of hypomagnesemia, hypokalemia, and hypocalcemia 15. <<<<<<<<<<< endotext.org lastly - and this is off the wall - these guys mention a research article about it as part of the research articles they use to talk about their product ... piercenet.com regards, John McCarthy

To: russet who wrote (30)	3/29/2004 8:30:05 PM
From: Peter H. Proctor	Read Replies (1) \| Respond to of 70

"The channel, called TRPM7, when activated causes brain cells to produce large quantities of free radicals - toxic molecules that break down the cell's DNA, proteins, and other components. Free radicals also cause TRPM7 to become even more active, causing massive overproduction of free radicals, resulting in death of the brain cell." TRPM7 or some related system likely plays a role in the action of nitrone drugs such as Cerovive, the disulfate derivative of PBN from Renovis. See nitrone.com . Peter H. Proctor, PhD, MD IP hit: Cerovive is the registered trademark for Astrazeneca's stroke drug NXY 059.